Astellas Pharma is aiming to double sales for its five key medicines, including Pfizer-partnered bladder cancer drug Padcev, through fiscal year 2030 under a new five-year strategy it published Tuesday.
Astellas Pharma is aiming to double sales for its five key medicines, including Pfizer-partnered bladder cancer drug Padcev, through fiscal year 2030 under a new …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Astellas Announces Five-Year Corporate Strategic Plan to Deliver Greater VALUE Faster for Patients and Position Itself as a Sustainable Growth Company
Astellas eyes more cost cuts; FDA panel to debate Moderna vaccine
Eliminating KRAS: Why targeted protein degraders could redefine what’s possible in cancer
Lilly, AbbVie, J&J, AZ lead an uptick in Big Pharma Q1 growth, with Novo again bringing up the rear
EU and US advisers split over AstraZeneca breast cancer drug
Europe's CHMP gives thumbs up to AZ's breast cancer drug after thumbs down from FDA adcomm
Astellas Announces Five-Year Corporate Strategic Plan to Deliver Greater VALUE Faster for Patients and Position Itself as a…
The Japanese pharma is aiming for $1.3 billion in yearly savings between now and 2030. Elsewhere, Datroway gained a new clearance…
AstraZeneca’s first foray with PD-L1 inhibitor Imfinzi as a treatment for bladder cancer was a flop. | Following an FDA approval…
AstraZeneca CEO Pascal Soriot aims for $80B annual sales by 2030; company on track with $58.7B in 2025, despite future loss of…
Novartis on Thursday forecast sales growth of 5% to 6% per year to 2030, on a currency-adjusted basis, as sales for cancer drugs…
Pfizer and its partner Arvinas are selling rights to their recently approved breast cancer drug to Rigel Pharmaceuticals.
